Abstract Introduction Pre‐exposure prophylaxis (PrEP) is an important HIV prevention
option. Two randomized trials have provided efficacy evidence for long‐acting injectable …

In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may
be offered as an additional HIV prevention option for people at substantial risk of HIV …

Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (ie, LAI-
PrEP) was approved by the US FDA in 2021. We sought to explore LAI-PrEP decision …

One hope surrounding long-acting HIV pre-exposure prophylaxis (PrEP) is reaching new
users who could most benefit, as well as improving the experiences of oral PrEP users who …

Long-acting injectable antiretroviral therapy (LAI ART) has the potential to address
adherence obstacles associated with daily oral ART, leading to enhanced treatment uptake …

Purpose To examine readiness to provide oral and injectable pre-exposure prophylaxis
(PrEP) for sexual and gender minority youth (SGMY) and to explore decision-making for HIV …

Background Long-acting injectable HIV pre-exposure prophylaxis (LAI-PrEP) was approved
by the US Food and Drug Administration in December 2021. This initial phase of …

Black sexual minority men (BSMM) are substantially less likely than White SMM to accept a
clinician's recommendation to initiate HIV pre-exposure prophylaxis (PrEP). The purpose of …

Long-acting injectables (LAIs) for HIV prevention and treatment could dramatically improve
health outcomes and health equity for people with HIV and those who could benefit from pre …

The introduction of injectable HIV pre-exposure prophylaxis (PrEP) has the potential to
significantly change the biomedical HIV prevention landscape. However, effective …